Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
The leading professional organisation for medical oncology
See you in Copenhagen to network and share ideas at this dedicated event for the lung community
Do patients with advanced endometrial cancer benefit from the addition of dostarlimab to first-line platinum-based chemotherapy?
The place to share your research, explore promising areas of development and engage with the international oncology community
A valuable assessment tool for practicing medical oncologists and an excellent opportunity for medical oncologists in training to assess their knowledge.
Learn the latest recommendations from the experts crafting and using the ESMO Guidelines in their daily practice and get your questions answered!
Gain a deeper understanding of the current and future therapies for the treatment of this tumour type. Watch live and get 2 ESMO-MORA category 1 points
Online application is now open until 9 May 2023
Online application is open until 4 April 2023
Online application is open until 10 April 2023
Online application is open until 3 April 2023
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
Droplet digital PCR detects BRAF allele fraction in ctDNA with high reproducibility and sensitivity, offering an alternative to NGS
Evidence for efficacy is based on the results from the Study CDRB436G2201
Findings from the NEOSTAR phase II platform study
Activating EZH2 mutations may define a new subset of aggressive Ewing sarcomas that benefit from treatment with an EZH2 inhibitor
Molecular genetic analyses of NETs hint at actionable therapeutic targets and potential predictive biomarkers of response to axitinib
Findings from a large comprehensive analysis do not support the evidence of a common genetic clonal alteration
This eUpdate on the ESMO Clinical Practice Guideline for prostate cancer includes updated treatment recommendations that consider treatment intensification and use of novel systemic agents
Findings from the ProtecT study after 15 years of follow-up
A Spanish study describes the genomic characterisation of neuroendocrine neoplasms as the first step towards more personalised management
Droplet digital PCR detects BRAF allele fraction in ctDNA with high reproducibility and sensitivity, offering an alternative to NGS
Evidence for efficacy is based on the results from the Study CDRB436G2201
Findings from the NEOSTAR phase II platform study
Findings from a large comprehensive analysis do not support the evidence of a common genetic clonal alteration
Findings from the ProtecT study after 15 years of follow-up
Findings from the DeFi study
DNA sequencing findings among patients with acute myeloid leukaemia in first remission prior to allogeneic haematopoietic cell transplant
Evidence for efficacy is based on the results from the monarchE study
Health-Related Quality-of-Life data from the KEYNOTE-826 study
ESMO is pleased to announce a combination of brand-new and well-established events happening in March, tackling two specific areas of oncology, with leading experts discussing novel clinical data and the latest treatment options
A total of 1,261,990 people will die from cancer in 2023 in the EU (EU-27). A further 172,314 people will die from the disease in the UK, according to new research published in the leading cancer journal Annals of Oncology today
The ESMO Targeted Anticancer Therapies Congress 2023, the gathering focusing on promising new anticancer targets and agents, with a particular emphasis on those in early phase clinical development, will be held in Paris, France, on 6-8 March 2023.
The ESMO Gynaecological Cancers Congress 2023, the annual event dedicated to improving the practice of gynaecological cancers specialists worldwide, will provide an overview of the latest treatments as well as insights into the biology and biomarkers of ovarian, uterine, cervical and even rare gynaecological cancers.
The European Society for Medical Oncology (ESMO) has developed a quality of life (QoL) checklist that is now integral to the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) - a validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
The ESMO Immuno-Oncology Congress 2022, an annual congress dedicated to the presentation and discussion of the latest scientific developments in this fast-moving field, will be held in person in Geneva, Switzerland, and virtually between 7-9 December.
More than 1.4 million men were diagnosed with prostate cancer in 2020 globally but the molecular characteristics of the disease remain unexplored for the majority of patients around the world.
The ESMO Asia Congress 2022 will be held in person in Singapore and virtually between 2-4 December 2022.
The Molecular Analysis for Precision Oncology Congress 2022 (MAP) is the yearly appointment where leading experts discuss current and future challenges in the rapidly developing field of precision oncology, with the aim of identifying targetable alterations through molecular profiling, to provide the best possible personalised treatment.
The European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) have announced today that the 2023 Heine H. Hansen Award is conferred on Paul Baas for his outstanding contribution to thoracic oncology research
ESMO has announced today that the 2023 ESMO TAT Honorary Award is presented to Susan Bates
ESMO is pleased to announce that the nomination process for the 2023 ESMO Society Awards is now open.
ESMO renews its support to World Cancer Day (WCD) joining the #CloseTheCareGap campaign led by the Union for International Cancer Control (UICC).
Andrés Cervantes started his two-year mandate as ESMO President on 1 January 2023.
Based on current knowledge available, they address key questions on safety and efficacy of COVID-19 vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose
ESMO President will act as an Advisor
With more than 2.2 million new cases and nearly 1.8 million deaths in 2020, lung cancer represents 11.4% of the 19,292,789 new cases of cancer worldwide and 18% of its mortality.
The European Society for Medical Oncology (ESMO) has announced today that the winner of the ESMO Award for Immuno-Oncology 2022 is conferred on Nina Bhardwaj for her outstanding contribution to cancer immunology research.
Molecular genetic analyses of NETs hint at actionable therapeutic targets and potential predictive biomarkers of response to axitinib
Activating EZH2 mutations may define a new subset of aggressive Ewing sarcomas that benefit from treatment with an EZH2 inhibitor
Facilitating an open dialogue with patients, to better understand their needs, makes research efforts more valuable in the long-term
A Spanish study describes the genomic characterisation of neuroendocrine neoplasms as the first step towards more personalised management
However, there are still many obstacles faced by investigators in achieving effective patient involvement in research
Continued collaboration to identify new molecular targets and treatments can build on existing success
Database studies in this rare cancer suggest that chemotherapy may provide survival benefit in node-positive tumours and that the KRAS G12D mutation could be a potential therapeutic target
Two studies presented by the French network TMRG-GINECO provide new insights into the treatment and quality of life of women with this rare cancer
Results from a study suggest that some existing inhibitors may benefit all subtypes of these rare malignancies, which currently lack effective treatments
From 2023 ASCO GU Cancers Symposium:
The KEYNOTE-057 trial has shown promising efficacy and safety of pembrolizumab monotherapy for BCG-unresponsive, papillary high-risk non-muscle-invasive bladder cancer
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
Switzerland
Virtual Meeting
Denmark
Switzerland
Argentina
Germany
Spain
United Arab Emirates
Netherlands
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
ESMO Members: the main session of the ESMO Examination 2023 will be held on Saturday 21 October during the ESMO Congress 2023.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
